Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Transitional Cell 12Urinary Bladder Neoplasms 9Ureteral Neoplasms 4Urologic Neoplasms 3Urethral Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Male Urogenital Diseases 1Head and Neck Neoplasms 1Female Urogenital Diseases 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1Adenocarcinoma of the Bladder 1

Interventions

pembrolizumab 4enfortumab vedotin 3Gemcitabine 3Cisplatin 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1testosterone 17 beta-cypionate 1temsirolimus 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1dodecyl maltoside 1Valproic Acid 1Testosterone Propionate 1Sunitinib 1Standard of Care 1Sirolimus 1Ringer's acetate 1Radiation Dose Hypofractionation 1Psychiatric Nursing 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Mitomycin 1Methyltestosterone 1Immunoglobulin G 1Fluorouracil 1Etoposide 1Doxycycline 1Disulfides 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urologic Neoplasms × enfortumab vedotin × 90 days × Clear all
NCT05614739 2026-05-19

FORAGER-1

Eli Lilly and Company

Phase 1 Recruiting
535 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡